Where Will Gilead Sciences, Inc. Be in 5 Years?

Gilead Sciences (NASDAQ: GILD) is in a slump. Over the past three years, the biotech's stock has lost over 35% of its value, thanks to falling hepatitis C sales, generic competition entering the HIV market in key geographies, and a slate of setbacks in hematology/oncology.